Advancing military healthcare: novel zwitterionic hydrogels for enhanced wound healing in combat-related burn injuries
Ended Purchase Order Awarded Last action
- Contract number
- FA864924P0508
- Awardee
-
Gelsana Therapeutics Inc. UEI CPRMRH9NFTF5
- Awarding agency
-
Air Force Research Laboratory
Air Force Materiel Command, Department of Defense
- Obligated
- $0
Award facts
- Contract value 0% obligated
- $1,249,624.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- 198 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Aurora, CO 80045, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,249,624 |
About this award
The U.S. Air Force Research Laboratory (AFRL) awarded a $1.25 million Phase II contract to Gelsana Therapeutics Inc., a woman-owned small business and HUBZone-certified firm, to develop novel zwitterionic hydrogels for enhanced wound healing in combat-related burn injuries. The contract, awarded on March 7, 2024, with completion targeted for October 2026, represents a firm fixed-price purchase order under the total small business set-aside program. This award follows Gelsana's Phase I SBIR contract (valued at $74,950 and awarded in May 2023) that explored zwitterionic hydrogel applications for burns, blast wounds, and chronic wounds, demonstrating the company's validated progress in this specialized technology domain.
Gelsana Therapeutics specializes in advanced biomaterial development with a core focus on creating controlled-release hydrogel systems that reduce inflammation and accelerate wound healing. The company's technical approach leverages zwitterionic chemistry to address critical medical needs in military healthcare contexts. Beyond this AFRL contract, Gelsana has expanded its therapeutic applications through parallel National Institute of Diabetes and Digestive and Kidney Diseases grants supporting diabetic wound healing solutions, including Provasliex Gel, a zwitterionic hydrogel designed for controlled platelet-derived growth factor delivery in diabetic foot ulcer management. This diversified portfolio underscores the company's commitment to translating military-relevant wound healing innovations into broader civilian healthcare applications.
Quick answers
Who was awarded contract FA864924P0508?
FA864924P0508 was awarded to Gelsana Therapeutics Inc. by Air Force Research Laboratory (Air Force Materiel Command) on March 7, 2024.
How much is contract FA864924P0508 worth?
The government has obligated $0 on FA864924P0508. Its current value, with exercised options, is $1,249,624.
Was contract FA864924P0508 competed?
The government received 198 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award